Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk

2025-06-03 18:28:07 ET

Summary

• Achieve Life Sciences (ACHV) is positioned for growth with its lead smoking cessation therapy, cytisinicline, advancing through late-stage clinical trials.
• The company addresses a significant unmet need in tobacco addiction, with cytisinicline showing promising efficacy and safety data compared to existing therapies.
• While FDA approval may be difficult, the low valuation and high potential peak sales provide a decent risk/reward profile.
• Given the large addressable market and strong clinical data, I rate ACHV a speculative buy for risk-tolerant investors seeking biotech exposure.

Introduction

Achieve Life Sciences, Inc. (ACHV) is a company focused on Cytisinicline, a smoking cessation oral therapy, that alters brain chemistry to counteract the effects of nicotine....

Read the full article on Seeking Alpha

For further details see: